NEU neuren pharmaceuticals limited

What are people hoping for. I've included my base case where...

  1. 2,540 Posts.
    lightbulb Created with Sketch. 691
    What are people hoping for. I've included my base case where anything above I think would be good, and anything

    1. Q4 revenue ($93m) and CY2024 revenue ($345m) (Midpoint)
    2. CY2025 guidance: North American Daybue Revenue 400bn+ (15%+)

    I think a slightly lower figure for Q4 may be okay provided the guidance/outlook is positive. I think a result of <91m for Q4 paired with a <370m for the full year 2025 could be poorly taken. I think a positive suprise would be >$93m for Q4 and >$400m for 2025 Daybue sales. 400m sales for Daybue is 15% growth in North America which might not seem like much but given Acadia's 1bn+ sales revenue and the analyst expectation of 1.05bn there's no positive expectations baked in at all, given Nuplazid is at a $600bn run rate and even if it grows 5% (630m) that only leaves 370m+ sales of Daybue to get to 1bn+ which is 7.25% YoY growth. Let's hope Acadia are internally looking for 1bn+ but aiming for 1.1m~ revenue for the full year combined Daybue and Nupazlid.
    Last edited by htae39: 26/02/25
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$14.20
Change
0.890(6.69%)
Mkt cap ! $1.761B
Open High Low Value Volume
$13.50 $14.26 $12.96 $9.111M 655.8K

Buyers (Bids)

No. Vol. Price($)
1 2000 $14.17
 

Sellers (Offers)

Price($) Vol. No.
$14.23 3278 1
View Market Depth
Last trade - 16.15pm 27/06/2025 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.